Anterolateral minithoracotomy versus median sternotomy for mitral valve disease: a meta-analysis

Abstract

Objective: Mitral valve disease tends to be treated with anterolateral minithoracotomy (ALMT) rather than median sternotomy (MS), as ALMT uses progressively smaller incisions to promote better cosmetic outcomes. This meta-analysis quantifies the effects of ALMT on surgical parameters and post-operative outcomes compared with MS. Methods: One randomized controlled study and four case-control studies, published in English from January 1996 to January 2013, were identified and evaluated. Results: ALMT showed a significantly longer cardiopulmonary bypass time (P=0.001) and aortic cross-clamp time (P=0.05) compared with MS. However, the benefits of ALMT were evident as demonstrated by a shorter length of hospital stay (P<0.00001). According to operative complications, the onset of new arrhythmias following ALMT decreased significantly as compared with MS (P=0.05); however, the incidence of peri-operative mortality (P=0.62), re-operation for bleeding (P=0.37), neurologic events (P=0.77), myocardial infarction (P=0.84), gastrointestinal complications (P=0.89), and renal insufficiency (P=0.67) were similar to these of MS. Long-term follow-up data were also examined, and revealed equivalent survival and freedom from mitral valve events. Conclusions: Current clinical data suggest that ALMT is a safe and effective alternative to the conventional approach and is associated with better short-term outcomes and a trend towards longer survival.

1. Introduction

Historically, most mitral valve surgery has been performed using conventional full median sternotomy (MS). In the late 1990s, a new procedure termed ‘minimally invasive mitral valve surgery’ (MIMVS) was being suggested (Cosgrove III et al., 1998; Gundry et al., 1998; Byrne et al., 2000; Gillinov et al., 2000). This procedure can minimize surgical trauma, resulting in reduced operative mortality, less pain, improved quality of life, and better cosmetic results by reducing the size of the incision, particularly for young females and older people (Walther et al., 1999; Soltesz and Cohn, 2007). MIMVS involves partial sternotomy, hemi-sternotomy, anterolateral minithoracotomy (ALMT), and total endoscopic approaches.

MIMVS is not a simple approach, rather a synthesis of new techniques and operation-specific technologies that are technically demanding and time-consuming. Most surgeons have regarded minimally invasive valve procedures as unnecessary and unsafe owing to limited exposure and increased technical difficulty, which may increase the risk of intra-operative myocardial and cerebral problems (Mohr et al., 1998; Vanermen et al., 1999; Glower et al., 2001). One recent review even suggested that demonstrable and reproducible benefits of the minimally invasive approach were restricted to cosmetic aspects (Anyanwu and Adams, 2012). Thus, the question remains as to whether the potential benefits of a minimally invasive approach can outweigh the potential drawbacks of limited operative exposure, longer cardiopulmonary bypass time and aortic cross-clamp time. One recent meta-analysis of minimal access mitral valve surgery (Modi et al., 2008), which collected data from 1996 to 2008, suggested some short- and long-term benefits for mortality, re-operation for bleeding, intensive care unit (ICU) stay, and hospital stay over conventional surgery, despite longer operative time. However, this meta-analysis included all kinds of minimally invasive approaches without any subgroups or randomized clinical trials.

ALMT is one of the most common minimally invasive approaches. The current preferred minimally invasive approach for the mitral valve is the right ALMT, which can be employed in those requiring concomitant management of tricuspid regurgitation or atrial fibrillation (Gillinov and Mihaljevic, 2012; Sündermann et al., 2012). A new meta-analysis specially focusing on ALMT for the last 17 years (1996–2013) of investigational data is needed. This new meta-analysis aims to provide evidence regarding the effects of ALMT compared with MS for the treatment of mitral valve disease.

For ALMT to be utilized widely, short-term outcomes and long-term results must be characterized and compared with those of MS. Additional evidence is required from large, multi-center prospective randomized controlled trials (RCTs) that compare ALMT with MS. However, it is unlikely that patients would participate in a trial with randomization to sternotomy as a control cohort because of preconceived notions. In the absence of large, well-designed RCTs, alternative data are available from multiple case-control studies.

2. Materials and methods

2.1. Search strategies

Searches for all relevant published articles were performed in Google Scholar, Medline, PubMed Central, and Embase databases from January 1996 to January 2013. The eligibility of every study having more than one author during the search was assessed. Search keywords were “minithoracotomy, median sternotomy, mitral”. To represent contemporary practice, the search was limited to the last 17 years, and additional limits were English language citations and human subjects. Reference lists of every relevant article were searched.

2.2. Inclusion and exclusion criteria

The studies were selected according to the following inclusion criteria: (1) the type of study: RCTs and case-control studies were used for the meta-analysis if they included at least one of the outcomes of interest; (2) participants: patients with mitral valve disease undergoing right ALMT.

The exclusion criteria were: (1) any other type of minimally invasive surgery, such as robotic surgery or endo-aortic balloon occlusion; (2) studies reporting re-operative data; (3) reports in a language other than English; (4) studies without a control group or with a control group that was not MS; (5) studies in which data were not presented as the mean and standard deviation (SD) or were not calculable; (6) studies in which the mitral data were not presented separately from other valve data.

2.3. Outcome measures

Only the outcome measures presented in more than two included studies were analyzed in our study. Cardiopulmonary bypass (CPB) time, aortic cross-clamp time (ACCT), length of hospital stay (LOHS), peri-operative mortality, and post-operative complications (re-operation for bleeding, neurologic events, gastrointestinal complications, arrhythmias, renal insufficiency, myocardial infarction, and sepsis) were selected for analysis.

2.4. Statistical analysis

Review Manager V.5.1 was used for statistical analysis. Meta-analyses were performed using either odds ratios (ORs) or weighted mean differences (WMDs) as the summary statistics for discontinuous or continuous variables, respectively. Statistical significance was set at P<0.05. We tested heterogeneity using the χ ² test, I ² test, and degrees of freedom. Random effects models were used presuming that outcome measures of each study were variable, and surgical data as selection criteria and risk profiles for patients differed among centers. In the present meta-analysis, the risk of bias was not assessed.

3. Results

Five published reports were identified: one RCT (Speziale et al., 2011) and four case-control studies (Felger et al., 2001; de Vaumas et al., 2003; Iribarne et al., 2010; Holzhey et al., 2011) (Table 1). Two studies, Chitwood et al. (1997) and Iribarne et al. (2012), were excluded because additional inclusive data were found from the same groups of Felger et al. (2001) and Iribarne et al. (2010), respectively. In total, we identified 379 studies by searching databases. Excluded studies were either meta-analyses (n=2), studies without the expected procedure (n=8), studies involving repair vs. replacement (n=1), studies with overlapping data (n=45), irrelevant studies (n=288), studies not in English (n=5), studies discussing other forms of valve surgery (n=4), studies of the same research (n=2), or studies without control groups (n=19). Ultimately, 31 studies were identified, in which 5 studies met the criteria stated above. A total of 1365 patients were included (replacement/repair=475/890). Additionally, regarding operation interventions, 660 of the studies involved ALMT and 705 involved MS (Fig. 1).

Table 1.

Characteristics of the five studies identified

Study	Period	No. of patients		Mean age (year)		Male/female		Replacement/repair		Design
		ALMT	MS	ALMT	MS	ALMT	MS	ALMT	MS
Felger et al. (2001)	Sept. 1996 to Nov. 2000	55	100	59	62	27/28	48/52	21/34	46/54	Case-control
de Vaumas et al. (2003)		10	10					Repair only	Repair only	Case-control
Iribarne et al. (2010)	Jan. 2000 to Dec. 2008	382	382	59.1	60.7	184/198	177/205	95/287	187/195	Case-control
Holzhey et al. (2011)	Aug. 1999 to July 2009	143	143	76	76	102/41	98/45	67/76	59/84	Case-control
Speziale et al. (2011)	From Jan. 2006	70	70	53.2	54	41/29	43/27	Repair only	Repair only	RCT

ALMT: anterolateral minithoracotomy; MS: median sternotomy; RCT: randomized controlled trial

Fig. 1.

Flow diagram of inclusion and exclusion criteria

This flow diagram illustrates the databases searched in this review, the resulting number of potential studies subject to our inclusion criteria, and the number and reasons for excluding studies based on our exclusion criteria

3.1. Operative time

Consistent evidence demonstrated that CPB time (1365 patients; WMD, 43.07 min longer, 95% confidence interval (CI): 17.42–68.73 min; P=0.001) and ACCT (1365 patients; WMD, 24.14 min longer; 95% CI: −0.13–48.41 min; P=0.05) were longer with ALMT when compared with MS, suggesting that ALMT was more technically demanding and time-consuming (Fig. 2).

Fig. 2.

Operative time of ALMT and MS in the five identified studies

Cardiopulmonary bypass (CPB) time and aortic cross-clamp time (ACCT) were significantly longer in the ALMT group than in the MS group

3.2. Peri-operative mortality

Peri-operative mortality is one of the most important outcome measures for evaluating efficiency and safety, defined as death from all causes within 30 post-operative days. One study with mortality data was excluded (Felger et al., 2001) because the mitral valve surgery data were mixed with those from aortic valve surgery. Only one randomized trial by Speziale et al. (2011) showed no difference in operative mortality (2/70 in ALMT vs. 1/70 in MS; P=0.99). Causes of death were stroke in one case, adult respiratory distress syndrome in one case, and post-operative low output in one case. Iribarne et al. (2010) showed no significant difference in peri-operative mortality (1.8% vs. 1.8%; P=0.622) or one-year mortality (5.0% vs. 3.9%; P=0.599) between the ALMT and MS groups. According to the results of the meta-analysis, three studies mentioned equivalent peri-operative mortality between ALMT and MS (Iribarne et al., 2010; Holzhey et al., 2011; Speziale et al., 2011), demonstrating no significant difference between these two procedures (1190 patients; OR=1.18, 95% CI: 0.61–2.30; P=0.62) (Table 2; Fig. 3).

Table 2.

Meta-analysis of post-operative adverse events

Outcome	No. of patients	No. of studies	OR/WMD (95% CI)	P	Heterogeneity
					χ 2	P
Peri-operative mortality	1190	3	1.18 (0.61–2.30)	0.62	0.30	0.86
Re-operation for bleeding	1345	4	1.27 (0.75–2.17)	0.37	3.06	0.38
Neurologic events	1345	4	0.84 (0.26–2.70)	0.77	4.50	0.21
Arrhythmias	1205	3	0.65 (0.43–0.99)	0.05	3.81	0.15
Myocardial infarction	1345	4	1.17 (0.27–5.07)	0.84	1.29	0.73
Gastrointestinal complications	1205	3	1.07 (0.40–2.87)	0.89	2.56	0.28
Renal insufficiency	1345	4	0.88 (0.48–1.60)	0.67	0.59	0.9

OR: odds ratio; WMD: weighted mean difference

Fig. 3.

Overall meta-analysis of outcome measures

The figure illustrates significant differences in arrhythmia and length of hospital stay, but no significant difference in other outcome measures

3.3. Re-operation for bleeding

One main advantage regarding ALMT relates to reduced blood loss and re-operation for bleeding. The largest study, by Iribarne et al. (2010), included 764 patients. The incidence of re-operation for bleeding in ALMT was found to be equivalent to that achieved with traditional sternotomy. Four studies met the inclusion criteria (Felger et al., 2001; Iribarne et al., 2010; Holzhey et al., 2011; Speziale et al., 2011) and showed no significant difference between ALMT and MS (OR=1.27, 95% CI: 0.75–2.17; P=0.37) (Table 2; Fig. 3).

3.4. Neurologic events

Some researchers suggest that neurologic events may occur with greater frequency in patients undergoing the minimally invasive approach because of inadequate de-airing (Anyanwu and Adams, 2012). The main neurologic events included transient/permanent stroke and ischemic attack. The morbidity of peri-operative neurologic events in the randomized trial by Speziale et al. (2011) was similar between ALMT and MS (1.4% vs. 2.8%; P=0.99). Further, no significant difference was found in four eligible studies (OR=0.84, 95% CI: 0.26–2.70; P=0.77) (Felger et al., 2001; Iribarne et al., 2010; Holzhey et al., 2011; Speziale et al., 2011) (Table 2; Fig. 3).

3.5. Arrhythmias and myocardial infarction

It is known that the less traumatic the cardiac procedure, the less potent the provoked peri-operative arrhythmias. Most peri-operative arrhythmias involve atrial fibrillation. Three studies in our meta-analysis found that 580 ALMT patients had less atrial fibrillation than 625 MS patients (OR=0.65, 95% CI: 0.43–0.99; P=0.05) (Felger et al., 2001; Iribarne et al., 2010; Holzhey et al., 2011) (Table 2; Fig. 3). The study by Asher et al. (1999), which was excluded for lack of a definition regarding the style of incision, showed a trend of low morbidity for atrial fibrillation in minimally invasive procedures compared with conventional sternotomy (28.6% vs. 40.0%; P=0.20).

It is known that peri-operative myocardial infarction can be induced by intra-operative coronary artery injury and thrombosis. Four studies have discussed this question (Felger et al., 2001; Iribarne et al., 2010; Holzhey et al., 2011; Speziale et al., 2011). However, no difference was found between ALMT and MS regarding peri-operative myocardial infarction (OR=1.17, 95% CI: 0.27–5.07; P=0.84) (Table 2; Fig. 3).

3.6. Gastrointestinal complications

Gastrointestinal complications always refer to stress ulcer and bleeding. Three studies with 1205 patients revealed no significant difference between ALMT and MS (OR=1.07, 95% CI: 0.40–2.87; P=0.89) (Felger et al., 2001; Iribarne et al., 2010; Holzhey et al., 2011) (Table 2; Fig. 3).

3.7. Renal insufficiency

Post-operative renal insufficiency is defined as an increase in the serum creatinine level greater than 2 mg/dl. The largest study, by Iribarne et al. (2010), showed that peri-operative renal failure was similar between ALMT and MS [7/382 (1.8%) vs. 5/382 (1.3%); P=0.773]. The RCT by Speziale et al. (2011) revealed the same result [3/70 (4.3%) vs. 3/70 (4.3%)]. Four studies that met the inclusion criteria (Felger et al., 2001; Iribarne et al., 2010; Holzhey et al., 2011; Speziale et al., 2011) showed no difference between ALMT and MS (OR=0.88, 95% CI: 0.48–1.60; P=0.67) (Table 2; Fig. 3).

3.8. Length of hospital stay, post-operative pain, and costs

Does a more rapid recovery translate into a shorter stay in the hospital and, therefore, reduced costs? LOHS is a measure of patient recovery following surgery. The LOHSs of the ALMT group in three studies were significantly shorter than those in the MS group (WMD, 2.95 d shorter, 95% CI: −3.45–−2.44 d; P<0.00001) (Fig. 3) (Felger et al., 2001; Holzhey et al., 2011; Speziale et al., 2011). However, additional multi-center studies should be performed in the future to compare recovery rates between ALMT and MS.

Less post-operative pain and a faster return to normal activity in ALMT are the most obvious advantages over MS. All three studies that measured post-operative pain levels reported less pain in ALMT compared with MS (Walther et al., 1999; Felger et al., 2001; Speziale et al., 2011). Speziale et al. (2011), the only randomized trial in our study, reported pain scores during the first 6 d after the operation. The mean pain scores were significantly lower in the ALMT group at all time points (the 2nd, 4th, and 6th post-operative days). In Felger et al. (2001), 11 re-operative patients who had a prior sternotomy for cardiac surgery reported less pain from ALMT and returned to regular activity more rapidly. Walther et al. (1999) revealed that patients undergoing ALMT had lower pain levels from the 3rd post-operative day onward.

Three studies recorded the reduced costs of the ALMT group compared with the MS group. Chitwood et al. (1997), Iribarne et al. (2012), and Cosgrove et al. (1998) equated this to $9165 (34%), $6721, and $420 (7%) in cost savings, respectively. Furthermore, discharge to the home, routinely or with a health aide, and satisfactory rehabilitation were more commonly reported in ALMT compared with MS, which can greatly save healthcare costs (Iribarne et al., 2012).

3.9. Long-term results

Long-term results included long-term survival and freedom from mitral valve events. Freedom from mitral valve events involved moderate to severe post-operative mitral regurgitation and any mitral re-operation. Anyanwu and Adams (2012) criticized the higher incidence of residual regurgitation by performing minimally invasive procedures in mitral valve repair. However, the only RCT, by Speziale et al. (2011), comparing 70 patients undergoing ALMT with 70 patients undergoing MS showed no significant difference in long-term survival (P=0.86) and freedom from mitral valve events (P=0.74). Other studies showed the same results as the RCT. The long-term survival ranged from (66.0±5.6)% to 100%, and the freedom from mitral valve surgery ranged from 66.0% to 97.8% (Table 3). According to our research, ALMT would not increase the incidence of post-operative mitral residual regurgitation and mitral re-operation.

Table 3.

Studies reporting long-term results of minimally invasive mitral valve surgery

Study	Institution	Long-term survival (%)		P	Freedom from mitral valve events (%)		P
		ALMT	MS		ALMT	MS
Aybek et al. (2006)	Frankfurt	90.7 (at 6.3 years)			96.2 (at 6.3 years)
Martin et al. (2006)	Durham	83±2 (at 5 years)			96±1 (at 5 years)
Seeburger et al. (2008)	Leipzig	82.6 (at 5 years)			96.3 (at 5 years)
Iribarne et al. (2010)	New York	91.9 (at 4 years)	91.9 (at 4 years)	0.569
Holzhey et al. (2011)	Leipzig	66±5.6 (at 5 years)	56±5.5 (at 5 years)	0.43
Speziale et al. (2011)	Bari	67 (at 2 years)	69 (at 2 years)	0.86	66 (at 2 years)	67 (at 2 years)	0.74
Reser et al. (2012)	Zürich	100 (at 1.8 years)			97.8 (at 1.8 years)

4. Discussion

In our study, we found that the potential benefits of ALMT, such as reduced incision size, can outweigh the potential drawbacks of limited operative exposure, longer CPB time and ACCT. Additionally, these potential benefits manifested as a more rapid recovery, which can translate into a shorter hospital stay and, therefore, reduced costs. Short- and long-term mortality rates were evaluated in our study. No significant difference was found between ALMT and MS in either peri-operative mortality or long-term survival. Conversely, the incidence of post-operative complications was similar between the ALMT and MS groups, except for fewer arrhythmias. All of the reviewed evidence demonstrated that ALMT is associated with equal mortality and incidence of post-operative adverse events.

Previously, endo-aortic balloon occlusion (EABO) was sometimes used in ALMT. However, surgeons increasingly discovered that EABO would increase the risk of aortic dissection and neurologic complications after operation compared with transthoracic clamping. Moreover, EABO was more expensive, more technically demanding, and less stable than transthoracic clamping. Thus, EABO has largely been replaced by transthoracic clamping (Aybek et al., 2000; Onnasch et al., 2002a; Reichenspurner et al., 2005).

“One-lung ventilation” was performed by two-lumen endotracheal intubation to fully expose the surgical field. Some studies have indicated that potential lung injury may be induced by one-lung hyperventilation, pulmonary stretch, and pleural damage (de Abreu et al., 2003; Gothard, 2006; Unzueta et al., 2007). However, according to our research, a more rapid recovery can be observed in the ALMT group compared with the MS group. Two studies (Felger et al., 2001; Holzhey et al., 2011) have demonstrated the incidence of post-operative respiratory complications between ALMT and MS. Holzhey et al. (2011) showed no significant difference in the incidence of post-operative respiratory failure between ALMT and MS (P>0.99). Felger et al. (2001) showed that the MS group was more likely to have prolonged ventilation (13% vs. 2%) and pneumonia (2% vs. 0%) compared with the ALMT group. Thus, there is no strong evidence that ALMT can induce more severe lung injury than MS.

ALMT has been used more extensively worldwide in place of conventional sternotomy for the treatment of mitral valve disease, particularly in females to improve cosmetic results. The incisions range from 4 to 8 cm and can be hidden in the submammary groove, while those of conventional MS are much longer and more unsightly. Murtuza et al. (2008) found that 282 of 308 patients (91.5%) were satisfied with the cosmetic result of ALMT. Three studies found that ALMT resulted in less pain and a higher quality of life in patients with mitral valve disease after operation (Walther et al., 1999; Felger et al., 2001; Speziale et al., 2011). Moreover, ALMT can maintain the continuity and integrity of the bony thorax, thereby preventing pectus carinatum and sternal infection.

Five meta-analyses have already been performed on minimal invasive heart surgery. Modi et al. (2008) showed that MIMVS was a safe and durable alternative to MS and was associated with equal mortality and neurologic events, less morbidity in terms of reduced incidence for re-operation for bleeding, a trend towards shorter hospital stay, less pain, and faster return to pre-operative function levels compared with conventional sternotomy, despite longer CPB time and ACCT. Ding et al. (2012) evaluated ALMT in congenital heart disease and suggested that this had a longer CPB time and ACCT, but shorter intubation time, ICU time, and LOHS. The remaining three studies compared a minimally invasive procedure with conventional sternotomy for aortic valve replacement (Murtuza et al., 2008; Brown et al., 2009; Khoshbin et al., 2011) and included RCTs and non-randomized studies. They concluded that a mini-sternotomy can be performed safely for aortic valve replacement without an increased risk of death, major complications (Khoshbin et al., 2011), a reduction in ICU stay time (Brown et al., 2009), or clinical benefit (Aybek et al., 2000). Moreover, we excluded 12 studies because they had no control groups (Loulmet et al., 1998; Mishra et al., 1999; Riess et al., 2001; Grossi et al., 2002; Onnasch et al., 2002b; Aybek et al., 2006; Martin et al., 2006; Seeburger et al., 2008; 2009; Glaubera et al., 2009; Müller et al., 2011; Reser et al., 2012), which ranged from 22 to 1339 in sample size. However, these studies, with 3085 patients in total, summarized the long-term clinical experience of ALMT, which is useful for making clinical decisions and ensuring the safety of ALMT.

One striking benefit of ALMT is the lesser rate of post-operative atrial fibrillation compared with MS. The mechanism, however, is not very clear. Asher et al. (1999) has shown that post-operative atrial fibrillation is often initiated from the left atrium. ALMT involves opening of the right atrium, followed by incision and entry to the mitral valve through the fossa ovalis. However, with median sternotomy, more often a conventional left atriotomy is performed for direct entry to the mitral valve. As a result, ALMT may be a less traumatic approach and therefore a less potent trigger of post-operative atrial fibrillation. Mathew et al. (2004) showed that bicaval venous cannulation (most often performed for mitral valve surgery) may predispose toward recurrent atrial fibrillation as a consequence of greater surgical injury. ALMT can avoid bicaval venous cannulation by using femoral cannulation instead.

Most selected studies included both high-risk and low-risk patients which were difficult to distinguish. Holzhey et al. (2011) had suggested that the outcome parameters are balanced between the groups of high-risk patients except for the strikingly reduced rate of post-operative atrial fibrillation in the ALMT group.

The present meta-analysis possesses limitations, such as the lack of large, multi-center prospective RCTs, concurrent tricuspid or septal defect repair, or atrial fibrillation ablation, and the different etiologies of mitral disease. Only one small RCT was identified. Thus, most of the studies were case-control studies. Random-effects models were applied because of variable outcome measures among studies and variable surgical data due to different selection criteria and patient characteristics among the different centers. As a result, the risk of bias was not assessed in the present meta-analysis. Hypothermic circulatory arrest time is a very important operative parameter for comparing ALMT with MS. However, all selected studies lacked these data. Some studies did not discuss the male to female ratio and the repair to replacement ratio, both of which can compromise the force of our research. Similarly, some patients in two of the selected reports (Iribarne et al., 2010; Holzhey et al., 2011) in our study did undertake not only isolated mitral valve repair, but also concurrent tricuspid or septal defect repair or atrial fibrillation ablation. Our study focussed on the type of the incision used in mitral surgery as the main criterion, rather than on etiology of mitral disease. Consequently, the study may result in an analysis of outcomes in a heterogeneous patient population with an unknown mix of ischemic, myxomatous, endocarditic, and rheumatic etiologies. Since the etiology of mitral valve disease is another important determinant of outcomes, this needs to be taken into account in the conclusions of this study. However, because all the studies lacked these data, it is difficult for us to require an analysis limited to a single pathology.

5. Conclusions

ALMT is a more complex surgical procedure with longer CPB time and ACCT than MS. However, ALMT can offer patients with mitral valve disease more benefits by a trend towards longer survival, shorter LOHS, and less post-operative arrhythmia than MS. The incidence of other peri-operative complications of ALMT is equivalent to that of MS.